The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: A retrospective analysis of the FEATHER study - Jakubowski, Joseph A.; Angiolillo, Dominick J.; Zhou, Chunmei; Small, David S.; Moser, Brian A.; ten Berg, Jurrien M.; Brown, Patricia B.; James, Stefan; Winters, Kenneth J.; Erlinge, David (Thrombosis research, 2014)
Keywords: Adult; Aged; Biomarkers - blood; Blood Platelets - drug effects; Blood Platelets - metabolism; Body Mass Index; Body Size; Body Surface Area; Body Weight; Cardiac and Cardiovascular Systems; Cardiology and Cardiovascular Disease; Cell Adhesion Molecules - blood; Clinical Medicine; Clopidogrel; Coronary Artery Disease - blood; Coronary Artery Disease - diagnosis; Coronary Artery Disease - drug therapy; Drug Dosage Calculations; Female; Hematology, Oncology and Palliative Medicine; Humans; Kardiologi; Kardiologi och kardiovaskulära sjukdomar; Klinisk medicin; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Microfilament Proteins - blood; Middle Aged; Pharmacodynamics; Pharmacokinetics; Phosphoproteins - blood; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - pharmacokinetics; Platelet Function Tests; Prasugrel; Prasugrel Hydrochloride - administration & dosage; Prasugrel Hydrochloride - pharmacokinetics; Purinergic P2Y Receptor Antagonists - administration & dosage; Purinergic P2Y Receptor Antagonists - pharmacokinetics; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12 - blood; Receptors, Purinergic P2Y12 - drug effects; Retrospective Studies; Ticlopidine - administration & dosage; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacokinetics; Treatment Outcome; PRI; Clop; TRITON-TIMI 38; ADP; AUC; PRP; BSA; PPP; Body mass index; R; PRU; BW; MD; HBW; BMI; LBW; VASP; Cmax; Pharmacodynamics; PGE1; CAD; MEA; AM; Prasugrel; ACS; Pras; PD; PCI; IRB; LD; LTA; Clopidogrel; PK; Pharmacokinetics; MPA; coronary artery disease; pharmacodynamics; multiple electrode aggregometry; body weight; percutaneous coronary intervention; low body weight; vasodilator-associated stimulated phosphoprotein; maximum platelet aggregation; adenosine diphosphate; prostaglandin E 1; body mass index; loading dose; high body weight; PGE 1; area under the concentration-time curve; maximum concentration